<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5136">
  <stage>Registered</stage>
  <submitdate>1/09/2015</submitdate>
  <approvaldate>1/09/2015</approvaldate>
  <nctid>NCT02539966</nctid>
  <trial_identification>
    <studytitle>Safety &amp; Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold</studytitle>
    <scientifictitle>Safety &amp; Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold</scientifictitle>
    <utrn />
    <trialacronym>FANTOM II</trialacronym>
    <secondaryid>HCT6200</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold

Experimental: Cohort A - Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group A (6-month angiographic follow-up)

Experimental: Cohort B - Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group B (9-month angiographic follow-up)

Experimental: Cohort C - Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group C (6-month angiographic follow-up), Long Lesion/Multi-Vessel


Treatment: devices: Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold
Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Major Adverse Cardiac Events (MACE) - Cohorts A, B and C - Cardiac Death, Myocardial Infarction (Q-Wave, Non Q-wave: CK-MB &gt;5X ULN) (MI), and target lesion revascularization (TLR)</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C - Late Lumen Loss</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Quantitative Coronary Angiography (QCA) derived parameters - Cohort B - Late Lumen Loss</outcome>
      <timepoint>9 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C - Minimum Lumen Diameter (MLD)</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quantitative Coronary Angiography (QCA) derived parameters - Cohort B - Minimum Lumen Diameter (MLD)</outcome>
      <timepoint>9 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C - % Diameter Stenosis</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quantitative Coronary Angiography (QCA) derived parameters - Cohort B - % Diameter Stenosis</outcome>
      <timepoint>9 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C - Binary Restenosis</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quantitative Coronary Angiography (QCA) derived parameters - Cohort B - Binary Restenosis</outcome>
      <timepoint>9 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major Adverse Cardiac Events (MACE) - Cohorts A, B and C - Cardiac Death, Myocardial Infarction (Q-Wave, Non Q-wave: CK-MB &gt;5X ULN) (MI), and target lesion revascularization (TLR)</outcome>
      <timepoint>12, 24, 36, 48 and 60 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - Cohorts A, B and C - Percentage of patients with TLR at each time point</outcome>
      <timepoint>12, 24, 36, 48 and 60 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - Cohorts A, B and C - Percentage of patients with TVR at each time point</outcome>
      <timepoint>12, 24, 36, 48 and 60 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Failure (TVF) - Cohorts A, B and C - Percentage of patients with TVF at each time point</outcome>
      <timepoint>12, 24, 36, 48 and 60 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Acute Technical Success - Cohorts A, B and C - Successful acute delivery and deployment of the device</outcome>
      <timepoint>Day 0</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Procedural Success - Cohorts A, B and C - Percentage of patients with angiographic success (final diameter stenosis &lt;50% without occurrence of MACE)</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient has evidence of myocardial ischemia or a positive functional study

          -  Target lesion has a visually estimated stenosis of =50% and &lt;100%

          -  Target lesion is located in a native coronary artery with average reference vessel
             diameter = 2.5mm and = 3.5mm

          -  Lesion length = 20 mm by visual estimate (N/A for Cohort C)

          -  Baseline TIMI flow = 2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  The patient has experienced an acute myocardial infarction (AMI: STEMI or NSTEMI)
             within 72 hours of the procedure and either CK-MB or Troponin has not returned to
             within 2X ULN.

          -  Patient has a left ventricular ejection fraction &lt; 40%

          -  Patient has unprotected left main coronary disease with =50% stenosis

          -  The target vessel is totally occluded (TIMI Flow 0 or 1)

          -  Target lesion involves a bifurcation (a lesion with a side branch = 1.5 mm in diameter
             containing a = 50% stenosis).

          -  Target lesion is located within a bypass graft

          -  Target lesion has possible or definite thrombus</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>220</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <hospital>St Vincent's Hospital Sydney - Darlinghurst</hospital>
    <hospital>Prince of Wales Hospital (Eastern Heart) - Randwick</hospital>
    <postcode> - Chermside</postcode>
    <postcode> - Darlinghurst</postcode>
    <postcode> - Randwick</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Aalst</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SÃ£o Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Massy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Coburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dortmund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>REVA Medical, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The FANTOM II trial is intended to assess safety and performance of the Fantom Bioresorbable
      Coronary Scaffold in native coronary arteries.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02539966</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Alexandre Abizaid, MD, PhD</name>
      <address>Instituto Dante Pazzanese de Cardiologia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Jeffrey Anderson</name>
      <address />
      <phone>858-966-3038</phone>
      <fax />
      <email>janderson@revamedical.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>